Search Results
Kahn, M., Jahan, S., Khaliq, S. és mtsai: Interaction of the hepatitis C virus (HCV) core with cellular genes in the development of HCV-induced steatosis. Arch. Virol., 2010, 155 , 1735
Roy, K., Hay, G., Andragetti, R. et al.: Monitoring hepatitis C virus infection among injecting drug users in the European Union: a review of the literature. Epidemiol. Infect., 2002, 129 , 577
mtsai: Report on the first trial with the HCV antibody test in Hungary. First Int. Meeting on Hepatitis C Virus, Rome, Sept. 14–15. 1989. Pár, A.: Antibody to hepatitis C virus in Hungary. Lancet
207 Watanabe, Y., Harada, S., Saito, I. és mtsai: Prevalence of antibody against the core protein of hepatitis C virus in patients with hepatocellular carcinoma. Int. J. Cancer
–361. 2 Pár, G., Berki, T., Pálinkás, L., et al.: Immunology of HCV infection: the causes of impaired cellular immune response and the effect of antiviral treatment. [A hepatitis C vírus
36 Alter, M. J.: Epidemiology of hepatitis C virus infection. World J. Gastroenterol., 2007, 13 , 2436–2441. Alter M. J
Bartenschlager, R., Cosset, F. L., Lohmann, V.: Hepatitis C virus replication cycle. J. Hepatol., 2010, 53 (3), 583–585. 4 Vermehren, J., Sarrazin, C.: New HCV therapies on
. T., et al.: A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. Liver Transpl., 2007, 13 , 975–983. Stravitz R. T
2483 Pawlotsky, J. M., Chevaliez, S., McHutchison, J. G.: The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology, 2007, 132 , 1979
results associated with the management of hepatitis C virus-induced diseases in Italy. Clinicoecon. Outcomes Res., 2014, 6, 303–310. 7 Vietri, J., Prajapati, G
